Company intelligence / Profile preview

Clavis Pharma

Ownership: Private
Development stage: Phase 2

Overview

Developed novel anti-cancer drugs using Lipid Vector Technology to improve efficacy and reduce side effects of established drugs. Lead product elacytarabine showed promising survival data in late-stage acute myeloid leukemia.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Small moleculesLipid-conjugated drugs
Industry: Biotech

Drug pipeline

1 asset

elacytarabine

Partnerships

Clovis Oncology ($380 million partnership in 2009, expanded to $205 million global rights deal in 2010)Translational Therapeutics, Inc.Mount Sinai School of Medicine

Beyond the preview

Go deeper on Clavis Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clavis Pharma.

Explore the full profile